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C hemotherapy-induced peripheral neuropathy (CIPN) has been problematic among patients 
with cancer who undergo chemotherapy.  The overall 
incidence of CIPN is estimated to be approx.  40% in 
patients treated with multiple agents [1 , 2].  With regard 
to the treatment of existing CIPN,  the best available 
data support a moderate recommendation for treatment 
with duloxetine [1].  Because there are no established 
preventive measures for CIPN due to the dearth of 
high-quality,  consistent evidence,  some patients expe-
rience severe CIPN,  resulting in a reduction in their 
quality of life and the cessation or dose reduction of 
chemotherapy [3 , 4].  CIPN can last for a long period,  
causing discomfort,  numbness,  or tingling in the hands 
or feet,  weakness or difficulty feeling small objects,  foot 
pain,  trouble walking,  and trouble working [5].
Taxanes are key drugs for patients with breast cancer 
in both adjuvant/neoadjuvant and metastatic disease 
settings.  The taxane docetaxel is used for adjuvant pur-
poses in patients with breast cancer,  as it improves the 
recurrence-free survival and overall survival of this 
patient population [2 , 4 , 6].  Docetaxel promotes the 
stabilization of microtubules and causes G2M cell-cycle 
arrest.  However,  CIPN is a major adverse effect associ-
ated with the administration of docetaxel,  with an any-
grade frequency reported to range from 25.5% to 64.4% 
[2 , 7] and grade 2-4 frequency at 35% [3].
In patients with breast cancer,  compression therapy 
using stockings and sleeves,  combined with medication 
using select prophylactic drugs such as the traditional 
Kampo medicine goshajinkigan (with the so-called “3S” 
approach) was reported to prevent or relieve CIPN that 
is due to another taxane,  nanoparticle albumin-bound 
paclitaxel (nab-PTX) [8].  Notably,  a meta-analysis 
indicated that goshajinkigan itself did not prevent CIPN 
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in patients undergoing neurotoxic chemotherapy [9].  
Tsuyuki et al.  [10].  showed that compression therapy 
using surgical gloves prevented the incidence and 
decreased the severity of CIPN in patients’ hands due to 
nab-PTX treatment.  While the two above-mentioned 
measures (medication and compression) seemed to 
have some degree of preventative effect on CIPN,  the 
proposal underlying the mechanisms differed (i.e.  
increased arteriole flow with minimal flow through cap-
illaries [8] and decreased microvascular flow [10],  
resulting in a decrease in the nab-PTX exposure to the 
peripheral nerve).
We have speculated that compression therapy alone 
(using stockings and sleeves) could be effective in pre-
venting or decreasing the severity of CIPN (in the feet 
and hands,  respectively).  Docetaxel and paclitaxel are 
two taxanes that have been particularly well investi-
gated,  especially in adjuvant/neoadjuvant settings [11-
13].  At our institute,  we have used docetaxel most fre-
quently in both adjuvant and neoadjuvant settings and 
for the treatment of metastatic disease.
The present study will assess the safety and efficacy 
of compression therapy using stockings and sleeves for 
preventing CIPN induced by docetaxel in patients with 
breast cancer.
Endpoints
Primary endpoint. The primary endpoint is the 
incidence of all-grade CIPN according to patients’ 
records until 3 weeks after the fourth docetaxel admin-
istration.
Secondary endpoints. The secondary endpoints 
are the (1) the incidence of CIPN by grade,  (2) the inci-
dence of all-grade CIPN according to the patients’ 
records at 3 weeks after each docetaxel administration,  
(3) the completion rate of the compression therapy,  (4) 
the incidence of adverse events due to the compression 
therapy,  (5) the completion rate of chemotherapy,  and 
(6) the relative dose intensity of the chemotherapy.
Eligibility Criteria
Eligible patients are women with histologically con-
firmed invasive breast cancer who are 20-79 years of age 
scheduled to receive docetaxel at a dose of 75 mg/m2 
intravenously every 3 weeks for 4 cycles as first-line 
chemotherapy for recurrent/metastatic disease or as 
neoadjuvant/adjuvant therapy.  Patients with human 
epidermal growth factor receptor 2 (HER2)-positive 
breast cancer will receive anti-HER2 agents before 
docetaxel in each cycle (trastuzumab; initial dose 
8 mg/kg,  loading dose 6 mg/kg).  In patients with dis-
tant metastasis or a high risk of recurrence who are 
receiving adjuvant/neoadjuvant therapy,  pertuzumab 
(initial dose 840 mg/kg,  loading dose 420 mg/kg) will 
also be administered after the trastuzumab administra-
tion.
Patients with peripheral neuropathy at baseline or 
receiving prior chemotherapy for any type of cancer will 
be excluded.  Patients with four cycles of epirubicin 
treatment with cyclophosphamide with or without 
5-fluorouracil given sequentially before docetaxel for 
adjuvant or neoadjuvant purposes will be allowed to 
participate.
Treatment Methods
Study design. This is a single-center,  single-arm,  
open-label historical control trial to evaluate the effect 
of compression therapy on preventing CIPN caused by 
docetaxel.  This study has been approved by the Clinical 
Research Review Board of Nagasaki University 
(CRB7180001) and has been registered in the Japan 
Registry of Clinical Trials (jRCT,  registration no. 
jRCTs072180038).  The protocol was designed and will 
be managed in accordance with the Declaration of 
Helsinki (1964) and the Clinical Trial Act (2018).
Recruitment, setting, and informed consent. The 
study design is illustrated in Fig. 1 As part of our routine 
clinical work,  we evaluate adverse events — including 
CIPN — in each cycle of chemotherapy.  For this study’s 
control group (without compression),  we collected data 
from 52 consecutive patients who met the above- 
described criteria between 2012 and 2016.  Patients in 
the intervention group were recruited from Nagasaki 
University from June 2017.  Women were recruited 
when they received the explanation of their chemother-
apy regimen.  All candidates were screened again to 
determine whether they were eligible for the study and 
were provided a participant information sheet and 
asked to provide their written consent.  Participants 
were informed that they had the right to withdraw from 
the study at any time without having to give a reason.
Treatment and assessment schedule. The patients 
will wear stockings (Okamoto Corp.,  Osaka,  Japan) 
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and sleeves (Okamoto Corp. ) for 24 h from the begin-
ning of docetaxel therapy [8].  There are four sizes of 
stockings or sleeves,  and the optimal size will be deter-
mined based on the circumference of the patient’s ankle 
and calf and her wrist and upper arm to obtain 
15-20 mmHg of pressure.
CIPN will be assessed by the treating surgeons or 
nurses using the Common Terminology Criteria for 
Adverse Events (CTCAE) version 4.0 at pretreatment,  
before each treatment cycle,  and at 3 weeks after the 
fourth docetaxel administration (Fig. 1).  All patients in 
this study received standard care for CIPN.  The patients 
will record their adherence to wearing stockings and 
sleeves and any relevant adverse events immediately 
before receiving cycles 2 to 4 and at 3 weeks after cycle 4 
of docetaxel (Fig. 1 , 2).
Safety monitoring. When a patient develops a 
severe adverse event in this study,  the investigator will 
report it to the principal investigator,  who will then 
inform all other investigators of the event and addition-
ally report it to The Clinical Research Review Board in 
Nagasaki University.
Data management. Data will be collected in 
case-report form and given a study code; de-identified 
data will be used for the analyses.  All hardcopies will be 
de-identified using the study code and stored securely in 
the hospital setting.  All data will be discarded 5 years 
after the completion of the study.
Statistical Considerations
The results of a previous study indicated that com-
pression therapy using stockings and sleeves and medi-
cation therapy using select prophylactic drugs,  includ-
ing goshajinkigan (the ‘3S’ approach),  reduced CIPN 
induced by nab-PTX from 100% to 65% of the patients 
[8].  Based on the retrospective data of 52 patients who 
were treated with docetaxel at our hospital between 
2012 and 2016,  the incidence of CIPN is 63% (the con-
trol group).  While we expect that compression therapy 
alone can reduce the rate of CIPN induced by docetaxel 
to a degree similar to that achieved by the 3S approach,  
the incidence of CIPN was ≤ 41% (63% multiplied by 
0.65) in the intervention group.  With a beta level of 0.2 
and an alpha level of 0.05 (one-sided),  we calculated 
that the trial would need to include 32 patients in the 
intervention group.  Therefore,  considering a 10% 
potential withdrawal rate,  we plan to enroll 35 patients.
Analyses of the primary and secondary outcomes 
will be based on an intention-to-treat analysis.  The 
patients’ clinicopathologic features will be compared 
between the intervention and control groups.  
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Control group (without compression) 
(n=52); 
Patients who took docetaxel 
between 2012 and 2016. Screening
Intervention group (n=35); 
Patients scheduled to take docetaxel.
Registration
1. Evaluation of CIPN 
2. Collection of patient’s
　 report 
3. Evaluation of adverse
　 events 
(before 2nd, 3rd, and 4th 
cycle, and three weeks after 
the 4th cycle)
Docetaxel therapy 
every 3 weeks for 4 cycles
Fig. 1　 Study design.  CIPN: chemotherapy-induced peripheral neuropathy.
Associations between variables will be assessed using 
Fisher’s exact test,  and all analyses will be one-sided at 
a significance level of 0.05.  All statistical analyses will be 
conducted with EZR (Saitama Medical Center,  Jichi 
Medical University,  Japan).
Discussion
In a 2014 study,  compression therapy using stock-
ings and sleeves plus medication therapy using select 
prophylactic drugs,  including goshajinkigan — the 
so-called ‘3S’ approach — was reported to prevent or 
relieve CIPN induced by the taxane nab-PTX [8].  
Goshajinkigan is a Japanese traditional drug composed 
of 10 medical herbs [14].  It has been shown to relieve 
diabetic neuropathy [15].  The suggested mechanisms 
by which goshajinkigan exerts a neuroprotective effect 
include the activation of κ-opioid receptors [16] and the 
promotion of nitric oxide production to improve the 
blood supply to the nerves [17],  caused mainly by the 
aconite root in goshajinkigan.  However,  because 
goshajinkigan itself was not shown to prevent CIPN in 
a meta-analysis [9],  we speculate that the effect of the 
3S approach for preventing CIPN could be achieved by 
compression only.
As noted above,  there are no established prophylac-
tic strategies against CIPN,  and some patients suffer 
from severe symptoms,  resulting in the reduction or 
cessation or change of drugs.  Moreover,  once CIPN 
occurs it can be difficult to treat,  and patients may suf-
fer from the symptoms for a long time (even after the 
taxane treatment is discontinued),  resulting in a 
decrease in the patient’s quality of life [18] and difficulty 
working [5].  If compression therapy as a prophylactic 
intervention can prevent CIPN effectively and safely,  
patients can take drugs at the desired relative dose 
intensity and still maintain a good quality of life.
The sleeves and stockings to be used in the present 
study are categorized as “general medical devices” and 
can promote the return of lymph flow and venous flow.  
They are readily available to the public,  and there have 
been no reports of severe side effects.  We expect that 
these compression devices will prevent CIPN in both 
the hands and feet.  If our study reveals that compres-
sion therapy is safe and effective for preventing CIPN 
due to docetaxel,  we will proceed to a phase III ran-
domized study.  Similar investigations should be per-
formed in patients receiving other chemotherapy for 
other types of cancer.
Trial status.　The trial is currently in the recruitment phase.  Recruit-
ment commenced in June 2017 and is expected to be completed by 
November 30,  2020.  Data collection will be completed by March 31,  2021.
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Were you able to wear the sleeves as instructed? Yes          No
If “No”, please describe your 1. reasons, and 2. 
details (How long you could wear them, etc.)
1.
2.
Were you able to wear the stockings as instructed? Yes          No
If “No”, please describe your 1. reasons, and 2. 
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1.
2.





Yes                No
Yes                No
Yes                No
Fig. 2　 Patient records.
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